These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25849113)

  • 1. An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive.
    Letchumanan M; Coyte PC; Loutfy M
    Antivir Ther; 2015; 20(6):613-21. PubMed ID: 25849113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.
    Leech AA; Burgess JF; Sullivan M; Kuohung W; Horný M; Drainoni ML; Christiansen CL; Linas BP
    AIDS; 2018 Nov; 32(18):2787-2798. PubMed ID: 30234602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a comprehensive safer conception intervention for HIV-serodiscordant couples in Kenya: uptake, use and effectiveness.
    Heffron R; Ngure K; Velloza J; Kiptinness C; Quame-Amalgo J; Oluch L; Thuo N; Njoroge J; Momanyi R; Gakuo S; Mbugua S; Morrison S; Haugen H; Chohan B; Celum C; Baeten JM; Mugo N
    J Int AIDS Soc; 2019 Apr; 22(4):e25261. PubMed ID: 30957420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States.
    Bazzi AR; Leech AA; Biancarelli DL; Sullivan M; Drainoni ML
    AIDS Patient Care STDS; 2017 Aug; 31(8):348-355. PubMed ID: 28719229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated costs for the delivery of safer conception strategies for HIV-discordant couples in Zimbabwe: a cost analysis.
    Hughes CS; Brown J; Murombedzi C; Chirenda T; Chareka G; Mhlanga F; Mateveke B; Gitome S; Makurumure T; Matubu A; Mgodi N; Chirenje Z; Kahn JG
    BMC Health Serv Res; 2020 Oct; 20(1):940. PubMed ID: 33046066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safer conception among HIV-1 serodiscordant couples in East Africa: understanding knowledge, attitudes, and experiences.
    Hancuch K; Baeten J; Ngure K; Celum C; Mugo N; Tindimwebwa E; Heffron R;
    AIDS Care; 2018 Aug; 30(8):973-981. PubMed ID: 29455572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
    Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering safer conception services to HIV serodiscordant couples in Kenya: perspectives from healthcare providers and HIV serodiscordant couples.
    Ngure K; Kimemia G; Dew K; Njuguna N; Mugo N; Celum C; Baeten JM; Heffron R
    J Int AIDS Soc; 2017 Mar; 20(Suppl 1):21309. PubMed ID: 28361508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
    Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
    J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility care interventions should be provided as the first line options for HIV+ serodiscordant couples who desire children in settings with affordable access to care, regardless of their fertility status.
    Zakarin Safier L; Sauer MV
    J Int AIDS Soc; 2017 Mar; 20(Suppl 1):21294. PubMed ID: 28361501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility Intentions, Pregnancy, and Use of PrEP and ART for Safer Conception Among East African HIV Serodiscordant Couples.
    Heffron R; Thomson K; Celum C; Haberer J; Ngure K; Mugo N; Bukusi E; Katabira E; Odoyo J; Bulya N; Asiimwe S; Tindimwebwa E; Baeten JM;
    AIDS Behav; 2018 Jun; 22(6):1758-1765. PubMed ID: 28894986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
    Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
    J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is PrEP necessary during natural conception in HIV-1-serodiscordant couples on ART with suppressed viral load? A retrospective cohort analysis.
    Sun L; Liu A; Li J; Shao Y; Li Q; Ye J; Zhang H; Li Z; Wang H
    BMC Infect Dis; 2020 Mar; 20(1):195. PubMed ID: 32138673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
    Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
    AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.